Pre-exposure prophylaxis with Evusheld™ elicits limited neutralizing activity against the omicron variant in kidney transplant patients Article Swipe
Iliès Benotmane
,
Aurélie Velay
,
Olivier Thaunat
,
Gabriela Gautier-Vargas
,
Jérôme Olagne
,
Samira Fafi–Kremer
,
Sophie Caillard
·
YOU?
·
· 2022
· Open Access
·
· DOI: https://doi.org/10.1101/2022.03.21.22272669
YOU?
·
· 2022
· Open Access
·
· DOI: https://doi.org/10.1101/2022.03.21.22272669
The combination of cilgavimab-tixagevimab (Evusheld™, Astra Zeneca) became the mainstay for protecting transplant recipients with poor response to vaccination against the omicron variant. Serum neutralizing capacity against SARS-CoV-2 is positively associated with protection against severe forms of Covid-19. Both anti-RBD IgG titers and neutralizing antibody titers against the omicron BA.1 variant were measured in serum samples collected from 63 adult kidney transplant recipients who received prophylactic injections of Evusheld™. Patients who received prophylactic Ronapreve™ (casirivimab-imdevimab, n = 39) and those who were infected with SARS-CoV-2 during the fifth wave of the pandemic (n = 14) served as negative and positive controls, respectively. After a median interval from injection of 29 days (interquartile range 29-33 days), only 9.5% of patients who received Evusheld™ were able to neutralize the omicron variant compared to 71% of patients who were infected with SARS-CoV-2 and 2.6% of those who received Ronapreve™. Interestingly, convalescent patients displayed higher levels of neutralizing antibodies than those who received EvusheldTM (median: 2.3 log IC50, IQR: 1.5-2.7 versus 0.00 log IC50, IQR: 0&[ndash] 0.05; p<0.001). A high interindividual variability in anti-RBD IgG titers was observed after Evusheld™ (range: 262-7032 BAU/mL). This variability was largely explained by the patients’body mass index, which showed an inverse correlation with anti-RBD IgG titers. These findings suggest that Evusheld™ given at a dose of 300 mg is not sufficient to elicit an anti-RDB titer that confers in vivo neutralizing activity and support recent FDA recommendations, derived from in vitro models, regarding the need to increase the dose of Evusheld™
Related Topics
Concepts
Metadata
- Type
- preprint
- Language
- en
- Landing Page
- https://doi.org/10.1101/2022.03.21.22272669
- https://www.medrxiv.org/content/medrxiv/early/2022/03/23/2022.03.21.22272669.full.pdf
- OA Status
- green
- Cited By
- 11
- References
- 5
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4220941629
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4220941629Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1101/2022.03.21.22272669Digital Object Identifier
- Title
-
Pre-exposure prophylaxis with Evusheld™ elicits limited neutralizing activity against the omicron variant in kidney transplant patientsWork title
- Type
-
preprintOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2022Year of publication
- Publication date
-
2022-03-23Full publication date if available
- Authors
-
Iliès Benotmane, Aurélie Velay, Olivier Thaunat, Gabriela Gautier-Vargas, Jérôme Olagne, Samira Fafi–Kremer, Sophie CaillardList of authors in order
- Landing page
-
https://doi.org/10.1101/2022.03.21.22272669Publisher landing page
- PDF URL
-
https://www.medrxiv.org/content/medrxiv/early/2022/03/23/2022.03.21.22272669.full.pdfDirect link to full text PDF
- Open access
-
YesWhether a free full text is available
- OA status
-
greenOpen access status per OpenAlex
- OA URL
-
https://www.medrxiv.org/content/medrxiv/early/2022/03/23/2022.03.21.22272669.full.pdfDirect OA link when available
- Concepts
-
Interquartile range, Medicine, Titer, Neutralizing antibody, Antibody, Antibody titer, Gastroenterology, Internal medicine, ImmunologyTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
11Total citation count in OpenAlex
- Citations by year (recent)
-
2025: 1, 2023: 1, 2022: 9Per-year citation counts (last 5 years)
- References (count)
-
5Number of works referenced by this work
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4220941629 |
|---|---|
| doi | https://doi.org/10.1101/2022.03.21.22272669 |
| ids.doi | https://doi.org/10.1101/2022.03.21.22272669 |
| ids.openalex | https://openalex.org/W4220941629 |
| fwci | 1.37699975 |
| type | preprint |
| title | Pre-exposure prophylaxis with Evusheld™ elicits limited neutralizing activity against the omicron variant in kidney transplant patients |
| biblio.issue | |
| biblio.volume | |
| biblio.last_page | |
| biblio.first_page | |
| topics[0].id | https://openalex.org/T10118 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 1.0 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2725 |
| topics[0].subfield.display_name | Infectious Diseases |
| topics[0].display_name | SARS-CoV-2 and COVID-19 Research |
| topics[1].id | https://openalex.org/T10041 |
| topics[1].field.id | https://openalex.org/fields/27 |
| topics[1].field.display_name | Medicine |
| topics[1].score | 0.9957000017166138 |
| topics[1].domain.id | https://openalex.org/domains/4 |
| topics[1].domain.display_name | Health Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2725 |
| topics[1].subfield.display_name | Infectious Diseases |
| topics[1].display_name | COVID-19 Clinical Research Studies |
| topics[2].id | https://openalex.org/T11754 |
| topics[2].field.id | https://openalex.org/fields/27 |
| topics[2].field.display_name | Medicine |
| topics[2].score | 0.9894000291824341 |
| topics[2].domain.id | https://openalex.org/domains/4 |
| topics[2].domain.display_name | Health Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2725 |
| topics[2].subfield.display_name | Infectious Diseases |
| topics[2].display_name | SARS-CoV-2 detection and testing |
| is_xpac | False |
| apc_list | |
| apc_paid | |
| concepts[0].id | https://openalex.org/C119060515 |
| concepts[0].level | 2 |
| concepts[0].score | 0.7740181684494019 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q1916617 |
| concepts[0].display_name | Interquartile range |
| concepts[1].id | https://openalex.org/C71924100 |
| concepts[1].level | 0 |
| concepts[1].score | 0.7362319231033325 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[1].display_name | Medicine |
| concepts[2].id | https://openalex.org/C32611913 |
| concepts[2].level | 3 |
| concepts[2].score | 0.7123326063156128 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q2166189 |
| concepts[2].display_name | Titer |
| concepts[3].id | https://openalex.org/C2779261636 |
| concepts[3].level | 3 |
| concepts[3].score | 0.6290296316146851 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q7003054 |
| concepts[3].display_name | Neutralizing antibody |
| concepts[4].id | https://openalex.org/C159654299 |
| concepts[4].level | 2 |
| concepts[4].score | 0.5295194983482361 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q79460 |
| concepts[4].display_name | Antibody |
| concepts[5].id | https://openalex.org/C22889606 |
| concepts[5].level | 4 |
| concepts[5].score | 0.5017960071563721 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q2166189 |
| concepts[5].display_name | Antibody titer |
| concepts[6].id | https://openalex.org/C90924648 |
| concepts[6].level | 1 |
| concepts[6].score | 0.4852040112018585 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q120569 |
| concepts[6].display_name | Gastroenterology |
| concepts[7].id | https://openalex.org/C126322002 |
| concepts[7].level | 1 |
| concepts[7].score | 0.3986256718635559 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[7].display_name | Internal medicine |
| concepts[8].id | https://openalex.org/C203014093 |
| concepts[8].level | 1 |
| concepts[8].score | 0.39423125982284546 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q101929 |
| concepts[8].display_name | Immunology |
| keywords[0].id | https://openalex.org/keywords/interquartile-range |
| keywords[0].score | 0.7740181684494019 |
| keywords[0].display_name | Interquartile range |
| keywords[1].id | https://openalex.org/keywords/medicine |
| keywords[1].score | 0.7362319231033325 |
| keywords[1].display_name | Medicine |
| keywords[2].id | https://openalex.org/keywords/titer |
| keywords[2].score | 0.7123326063156128 |
| keywords[2].display_name | Titer |
| keywords[3].id | https://openalex.org/keywords/neutralizing-antibody |
| keywords[3].score | 0.6290296316146851 |
| keywords[3].display_name | Neutralizing antibody |
| keywords[4].id | https://openalex.org/keywords/antibody |
| keywords[4].score | 0.5295194983482361 |
| keywords[4].display_name | Antibody |
| keywords[5].id | https://openalex.org/keywords/antibody-titer |
| keywords[5].score | 0.5017960071563721 |
| keywords[5].display_name | Antibody titer |
| keywords[6].id | https://openalex.org/keywords/gastroenterology |
| keywords[6].score | 0.4852040112018585 |
| keywords[6].display_name | Gastroenterology |
| keywords[7].id | https://openalex.org/keywords/internal-medicine |
| keywords[7].score | 0.3986256718635559 |
| keywords[7].display_name | Internal medicine |
| keywords[8].id | https://openalex.org/keywords/immunology |
| keywords[8].score | 0.39423125982284546 |
| keywords[8].display_name | Immunology |
| language | en |
| locations[0].id | doi:10.1101/2022.03.21.22272669 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S4306402567 |
| locations[0].source.issn | |
| locations[0].source.type | repository |
| locations[0].source.is_oa | False |
| locations[0].source.issn_l | |
| locations[0].source.is_core | False |
| locations[0].source.is_in_doaj | False |
| locations[0].source.display_name | bioRxiv (Cold Spring Harbor Laboratory) |
| locations[0].source.host_organization | https://openalex.org/I2750212522 |
| locations[0].source.host_organization_name | Cold Spring Harbor Laboratory |
| locations[0].source.host_organization_lineage | https://openalex.org/I2750212522 |
| locations[0].license | cc-by-nc-nd |
| locations[0].pdf_url | https://www.medrxiv.org/content/medrxiv/early/2022/03/23/2022.03.21.22272669.full.pdf |
| locations[0].version | acceptedVersion |
| locations[0].raw_type | posted-content |
| locations[0].license_id | https://openalex.org/licenses/cc-by-nc-nd |
| locations[0].is_accepted | True |
| locations[0].is_published | False |
| locations[0].raw_source_name | |
| locations[0].landing_page_url | https://doi.org/10.1101/2022.03.21.22272669 |
| indexed_in | crossref |
| authorships[0].author.id | https://openalex.org/A5042884943 |
| authorships[0].author.orcid | https://orcid.org/0000-0001-9113-2479 |
| authorships[0].author.display_name | Iliès Benotmane |
| authorships[0].countries | FR |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I68947357 |
| authorships[0].affiliations[0].raw_affiliation_string | Department of Nephrology and Transplantation, Strasbourg University Hospital, 67000 Strasbourg, France |
| authorships[0].institutions[0].id | https://openalex.org/I68947357 |
| authorships[0].institutions[0].ror | https://ror.org/00pg6eq24 |
| authorships[0].institutions[0].type | education |
| authorships[0].institutions[0].lineage | https://openalex.org/I68947357 |
| authorships[0].institutions[0].country_code | FR |
| authorships[0].institutions[0].display_name | Université de Strasbourg |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Ilies Benotmane |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | Department of Nephrology and Transplantation, Strasbourg University Hospital, 67000 Strasbourg, France |
| authorships[1].author.id | https://openalex.org/A5027080443 |
| authorships[1].author.orcid | https://orcid.org/0000-0002-9174-8959 |
| authorships[1].author.display_name | Aurélie Velay |
| authorships[1].affiliations[0].raw_affiliation_string | Department of Virology, Strasbourg University Hospital, 67000 Strasbourg, France |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Aurélie Velay |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | Department of Virology, Strasbourg University Hospital, 67000 Strasbourg, France |
| authorships[2].author.id | https://openalex.org/A5066933536 |
| authorships[2].author.orcid | https://orcid.org/0000-0002-3648-8963 |
| authorships[2].author.display_name | Olivier Thaunat |
| authorships[2].countries | FR |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I4210100596 |
| authorships[2].affiliations[0].raw_affiliation_string | Hospices Civils de Lyon, Edouard Herriot Hospital, Department of Transplantation, Nephrology and Clinical Immunology, 5, place d'Arsonval, 6900 Lyon, France |
| authorships[2].institutions[0].id | https://openalex.org/I4210100596 |
| authorships[2].institutions[0].ror | https://ror.org/01502ca60 |
| authorships[2].institutions[0].type | healthcare |
| authorships[2].institutions[0].lineage | https://openalex.org/I4210100596 |
| authorships[2].institutions[0].country_code | FR |
| authorships[2].institutions[0].display_name | Hospices Civils de Lyon |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Olivier Thaunat |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | Hospices Civils de Lyon, Edouard Herriot Hospital, Department of Transplantation, Nephrology and Clinical Immunology, 5, place d'Arsonval, 6900 Lyon, France |
| authorships[3].author.id | https://openalex.org/A5057958868 |
| authorships[3].author.orcid | https://orcid.org/0000-0001-9377-1055 |
| authorships[3].author.display_name | Gabriela Gautier-Vargas |
| authorships[3].countries | FR |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I68947357 |
| authorships[3].affiliations[0].raw_affiliation_string | Department of Nephrology and Transplantation, Strasbourg University Hospital, 67000 Strasbourg, France |
| authorships[3].institutions[0].id | https://openalex.org/I68947357 |
| authorships[3].institutions[0].ror | https://ror.org/00pg6eq24 |
| authorships[3].institutions[0].type | education |
| authorships[3].institutions[0].lineage | https://openalex.org/I68947357 |
| authorships[3].institutions[0].country_code | FR |
| authorships[3].institutions[0].display_name | Université de Strasbourg |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Gabriela Gautier Vargas |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | Department of Nephrology and Transplantation, Strasbourg University Hospital, 67000 Strasbourg, France |
| authorships[4].author.id | https://openalex.org/A5022800203 |
| authorships[4].author.orcid | https://orcid.org/0000-0001-6792-5399 |
| authorships[4].author.display_name | Jérôme Olagne |
| authorships[4].countries | FR |
| authorships[4].affiliations[0].institution_ids | https://openalex.org/I68947357 |
| authorships[4].affiliations[0].raw_affiliation_string | Department of Nephrology and Transplantation, Strasbourg University Hospital, 67000 Strasbourg, France |
| authorships[4].institutions[0].id | https://openalex.org/I68947357 |
| authorships[4].institutions[0].ror | https://ror.org/00pg6eq24 |
| authorships[4].institutions[0].type | education |
| authorships[4].institutions[0].lineage | https://openalex.org/I68947357 |
| authorships[4].institutions[0].country_code | FR |
| authorships[4].institutions[0].display_name | Université de Strasbourg |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Jérôme Olagne |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | Department of Nephrology and Transplantation, Strasbourg University Hospital, 67000 Strasbourg, France |
| authorships[5].author.id | https://openalex.org/A5107092670 |
| authorships[5].author.orcid | https://orcid.org/0000-0003-3886-7833 |
| authorships[5].author.display_name | Samira Fafi–Kremer |
| authorships[5].affiliations[0].raw_affiliation_string | Department of Virology, Strasbourg University Hospital, 67000 Strasbourg, France |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | Samira Fafi-Kremer |
| authorships[5].is_corresponding | False |
| authorships[5].raw_affiliation_strings | Department of Virology, Strasbourg University Hospital, 67000 Strasbourg, France |
| authorships[6].author.id | https://openalex.org/A5076266774 |
| authorships[6].author.orcid | https://orcid.org/0000-0002-0525-4291 |
| authorships[6].author.display_name | Sophie Caillard |
| authorships[6].countries | FR |
| authorships[6].affiliations[0].institution_ids | https://openalex.org/I68947357 |
| authorships[6].affiliations[0].raw_affiliation_string | Department of Nephrology and Transplantation, Strasbourg University Hospital, 67000 Strasbourg, France |
| authorships[6].institutions[0].id | https://openalex.org/I68947357 |
| authorships[6].institutions[0].ror | https://ror.org/00pg6eq24 |
| authorships[6].institutions[0].type | education |
| authorships[6].institutions[0].lineage | https://openalex.org/I68947357 |
| authorships[6].institutions[0].country_code | FR |
| authorships[6].institutions[0].display_name | Université de Strasbourg |
| authorships[6].author_position | last |
| authorships[6].raw_author_name | Sophie Caillard |
| authorships[6].is_corresponding | True |
| authorships[6].raw_affiliation_strings | Department of Nephrology and Transplantation, Strasbourg University Hospital, 67000 Strasbourg, France |
| has_content.pdf | True |
| has_content.grobid_xml | True |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://www.medrxiv.org/content/medrxiv/early/2022/03/23/2022.03.21.22272669.full.pdf |
| open_access.oa_status | green |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | Pre-exposure prophylaxis with Evusheld™ elicits limited neutralizing activity against the omicron variant in kidney transplant patients |
| has_fulltext | True |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T10118 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 1.0 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2725 |
| primary_topic.subfield.display_name | Infectious Diseases |
| primary_topic.display_name | SARS-CoV-2 and COVID-19 Research |
| related_works | https://openalex.org/W2363693236, https://openalex.org/W391733525, https://openalex.org/W1678510290, https://openalex.org/W1991270129, https://openalex.org/W2374971639, https://openalex.org/W3176239880, https://openalex.org/W2052465442, https://openalex.org/W1994916440, https://openalex.org/W4300690742, https://openalex.org/W3185521317 |
| cited_by_count | 11 |
| counts_by_year[0].year | 2025 |
| counts_by_year[0].cited_by_count | 1 |
| counts_by_year[1].year | 2023 |
| counts_by_year[1].cited_by_count | 1 |
| counts_by_year[2].year | 2022 |
| counts_by_year[2].cited_by_count | 9 |
| locations_count | 1 |
| best_oa_location.id | doi:10.1101/2022.03.21.22272669 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S4306402567 |
| best_oa_location.source.issn | |
| best_oa_location.source.type | repository |
| best_oa_location.source.is_oa | False |
| best_oa_location.source.issn_l | |
| best_oa_location.source.is_core | False |
| best_oa_location.source.is_in_doaj | False |
| best_oa_location.source.display_name | bioRxiv (Cold Spring Harbor Laboratory) |
| best_oa_location.source.host_organization | https://openalex.org/I2750212522 |
| best_oa_location.source.host_organization_name | Cold Spring Harbor Laboratory |
| best_oa_location.source.host_organization_lineage | https://openalex.org/I2750212522 |
| best_oa_location.license | cc-by-nc-nd |
| best_oa_location.pdf_url | https://www.medrxiv.org/content/medrxiv/early/2022/03/23/2022.03.21.22272669.full.pdf |
| best_oa_location.version | acceptedVersion |
| best_oa_location.raw_type | posted-content |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by-nc-nd |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | False |
| best_oa_location.raw_source_name | |
| best_oa_location.landing_page_url | https://doi.org/10.1101/2022.03.21.22272669 |
| primary_location.id | doi:10.1101/2022.03.21.22272669 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S4306402567 |
| primary_location.source.issn | |
| primary_location.source.type | repository |
| primary_location.source.is_oa | False |
| primary_location.source.issn_l | |
| primary_location.source.is_core | False |
| primary_location.source.is_in_doaj | False |
| primary_location.source.display_name | bioRxiv (Cold Spring Harbor Laboratory) |
| primary_location.source.host_organization | https://openalex.org/I2750212522 |
| primary_location.source.host_organization_name | Cold Spring Harbor Laboratory |
| primary_location.source.host_organization_lineage | https://openalex.org/I2750212522 |
| primary_location.license | cc-by-nc-nd |
| primary_location.pdf_url | https://www.medrxiv.org/content/medrxiv/early/2022/03/23/2022.03.21.22272669.full.pdf |
| primary_location.version | acceptedVersion |
| primary_location.raw_type | posted-content |
| primary_location.license_id | https://openalex.org/licenses/cc-by-nc-nd |
| primary_location.is_accepted | True |
| primary_location.is_published | False |
| primary_location.raw_source_name | |
| primary_location.landing_page_url | https://doi.org/10.1101/2022.03.21.22272669 |
| publication_date | 2022-03-23 |
| publication_year | 2022 |
| referenced_works | https://openalex.org/W3202923037, https://openalex.org/W4206193383, https://openalex.org/W4221072241, https://openalex.org/W4210249750, https://openalex.org/W4220955692 |
| referenced_works_count | 5 |
| abstract_inverted_index.= | 77, 94 |
| abstract_inverted_index.A | 175 |
| abstract_inverted_index.a | 104, 216 |
| abstract_inverted_index.n | 76 |
| abstract_inverted_index.(n | 93 |
| abstract_inverted_index.29 | 110 |
| abstract_inverted_index.63 | 59 |
| abstract_inverted_index.an | 202, 226 |
| abstract_inverted_index.as | 97 |
| abstract_inverted_index.at | 215 |
| abstract_inverted_index.by | 195 |
| abstract_inverted_index.in | 54, 179, 231, 242 |
| abstract_inverted_index.is | 29, 221 |
| abstract_inverted_index.mg | 220 |
| abstract_inverted_index.of | 3, 37, 68, 90, 109, 118, 133, 142, 153, 218, 252 |
| abstract_inverted_index.to | 18, 125, 131, 224, 248 |
| abstract_inverted_index.14) | 95 |
| abstract_inverted_index.2.3 | 162 |
| abstract_inverted_index.300 | 219 |
| abstract_inverted_index.39) | 78 |
| abstract_inverted_index.71% | 132 |
| abstract_inverted_index.FDA | 238 |
| abstract_inverted_index.IgG | 41, 181, 207 |
| abstract_inverted_index.The | 1 |
| abstract_inverted_index.and | 43, 79, 99, 140, 235 |
| abstract_inverted_index.for | 11 |
| abstract_inverted_index.log | 163, 169 |
| abstract_inverted_index.not | 222 |
| abstract_inverted_index.the | 9, 21, 48, 87, 91, 127, 196, 246, 250 |
| abstract_inverted_index.was | 183, 192 |
| abstract_inverted_index.who | 64, 71, 81, 120, 135, 144, 158 |
| abstract_inverted_index.0.00 | 168 |
| abstract_inverted_index.2.6% | 141 |
| abstract_inverted_index.9.5% | 117 |
| abstract_inverted_index.BA.1 | 50 |
| abstract_inverted_index.Both | 39 |
| abstract_inverted_index.IQR: | 165, 171 |
| abstract_inverted_index.This | 190 |
| abstract_inverted_index.able | 124 |
| abstract_inverted_index.days | 111 |
| abstract_inverted_index.dose | 217, 251 |
| abstract_inverted_index.from | 58, 107, 241 |
| abstract_inverted_index.high | 176 |
| abstract_inverted_index.mass | 198 |
| abstract_inverted_index.need | 247 |
| abstract_inverted_index.only | 116 |
| abstract_inverted_index.poor | 16 |
| abstract_inverted_index.than | 156 |
| abstract_inverted_index.that | 212, 229 |
| abstract_inverted_index.vivo | 232 |
| abstract_inverted_index.wave | 89 |
| abstract_inverted_index.were | 52, 82, 123, 136 |
| abstract_inverted_index.with | 15, 32, 84, 138, 205 |
| abstract_inverted_index.0.05; | 173 |
| abstract_inverted_index.29-33 | 114 |
| abstract_inverted_index.After | 103 |
| abstract_inverted_index.Astra | 6 |
| abstract_inverted_index.IC50, | 164, 170 |
| abstract_inverted_index.Serum | 24 |
| abstract_inverted_index.These | 209 |
| abstract_inverted_index.adult | 60 |
| abstract_inverted_index.after | 185 |
| abstract_inverted_index.fifth | 88 |
| abstract_inverted_index.forms | 36 |
| abstract_inverted_index.given | 214 |
| abstract_inverted_index.range | 113 |
| abstract_inverted_index.serum | 55 |
| abstract_inverted_index.those | 80, 143, 157 |
| abstract_inverted_index.titer | 228 |
| abstract_inverted_index.vitro | 243 |
| abstract_inverted_index.which | 200 |
| abstract_inverted_index.became | 8 |
| abstract_inverted_index.days), | 115 |
| abstract_inverted_index.during | 86 |
| abstract_inverted_index.elicit | 225 |
| abstract_inverted_index.higher | 151 |
| abstract_inverted_index.index, | 199 |
| abstract_inverted_index.kidney | 61 |
| abstract_inverted_index.levels | 152 |
| abstract_inverted_index.median | 105 |
| abstract_inverted_index.recent | 237 |
| abstract_inverted_index.served | 96 |
| abstract_inverted_index.severe | 35 |
| abstract_inverted_index.showed | 201 |
| abstract_inverted_index.titers | 42, 46, 182 |
| abstract_inverted_index.versus | 167 |
| abstract_inverted_index.(range: | 187 |
| abstract_inverted_index.1.5-2.7 | 166 |
| abstract_inverted_index.Zeneca) | 7 |
| abstract_inverted_index.against | 20, 27, 34, 47 |
| abstract_inverted_index.confers | 230 |
| abstract_inverted_index.derived | 240 |
| abstract_inverted_index.inverse | 203 |
| abstract_inverted_index.largely | 193 |
| abstract_inverted_index.models, | 244 |
| abstract_inverted_index.omicron | 22, 49, 128 |
| abstract_inverted_index.samples | 56 |
| abstract_inverted_index.suggest | 211 |
| abstract_inverted_index.support | 236 |
| abstract_inverted_index.titers. | 208 |
| abstract_inverted_index.variant | 51, 129 |
| abstract_inverted_index.(median: | 161 |
| abstract_inverted_index.262-7032 | 188 |
| abstract_inverted_index.Abstract | 0 |
| abstract_inverted_index.BAU/mL). | 189 |
| abstract_inverted_index.Patients | 70 |
| abstract_inverted_index.activity | 234 |
| abstract_inverted_index.anti-RBD | 40, 180, 206 |
| abstract_inverted_index.anti-RDB | 227 |
| abstract_inverted_index.antibody | 45 |
| abstract_inverted_index.capacity | 26 |
| abstract_inverted_index.compared | 130 |
| abstract_inverted_index.findings | 210 |
| abstract_inverted_index.increase | 249 |
| abstract_inverted_index.infected | 83, 137 |
| abstract_inverted_index.interval | 106 |
| abstract_inverted_index.mainstay | 10 |
| abstract_inverted_index.measured | 53 |
| abstract_inverted_index.negative | 98 |
| abstract_inverted_index.observed | 184 |
| abstract_inverted_index.pandemic | 92 |
| abstract_inverted_index.patients | 119, 134, 149 |
| abstract_inverted_index.positive | 100 |
| abstract_inverted_index.received | 65, 72, 121, 145, 159 |
| abstract_inverted_index.response | 17 |
| abstract_inverted_index.variant. | 23 |
| abstract_inverted_index.Covid-19. | 38 |
| abstract_inverted_index.collected | 57 |
| abstract_inverted_index.controls, | 101 |
| abstract_inverted_index.displayed | 150 |
| abstract_inverted_index.explained | 194 |
| abstract_inverted_index.injection | 108 |
| abstract_inverted_index.regarding | 245 |
| abstract_inverted_index.EvusheldTM | 160 |
| abstract_inverted_index.SARS-CoV-2 | 28, 85, 139 |
| abstract_inverted_index.antibodies | 155 |
| abstract_inverted_index.associated | 31 |
| abstract_inverted_index.injections | 67 |
| abstract_inverted_index.neutralize | 126 |
| abstract_inverted_index.positively | 30 |
| abstract_inverted_index.protecting | 12 |
| abstract_inverted_index.protection | 33 |
| abstract_inverted_index.recipients | 14, 63 |
| abstract_inverted_index.sufficient | 223 |
| abstract_inverted_index.transplant | 13, 62 |
| abstract_inverted_index.Evusheld™ | 122, 186, 213, 253 |
| abstract_inverted_index.combination | 2 |
| abstract_inverted_index.correlation | 204 |
| abstract_inverted_index.vaccination | 19 |
| abstract_inverted_index.variability | 178, 191 |
| abstract_inverted_index.Evusheld™. | 69 |
| abstract_inverted_index.Ronapreve™ | 74 |
| abstract_inverted_index.convalescent | 148 |
| abstract_inverted_index.neutralizing | 25, 44, 154, 233 |
| abstract_inverted_index.p<0.001). | 174 |
| abstract_inverted_index.prophylactic | 66, 73 |
| abstract_inverted_index.(Evusheld™, | 5 |
| abstract_inverted_index.0&[ndash] | 172 |
| abstract_inverted_index.Ronapreve™. | 146 |
| abstract_inverted_index.respectively. | 102 |
| abstract_inverted_index.(interquartile | 112 |
| abstract_inverted_index.Interestingly, | 147 |
| abstract_inverted_index.interindividual | 177 |
| abstract_inverted_index.patients’body | 197 |
| abstract_inverted_index.recommendations, | 239 |
| abstract_inverted_index.cilgavimab-tixagevimab | 4 |
| abstract_inverted_index.(casirivimab-imdevimab, | 75 |
| cited_by_percentile_year.max | 99 |
| cited_by_percentile_year.min | 89 |
| corresponding_author_ids | https://openalex.org/A5076266774 |
| countries_distinct_count | 1 |
| institutions_distinct_count | 7 |
| corresponding_institution_ids | https://openalex.org/I68947357 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/3 |
| sustainable_development_goals[0].score | 0.8199999928474426 |
| sustainable_development_goals[0].display_name | Good health and well-being |
| citation_normalized_percentile.value | 0.79090558 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |